SP 996-2026 Acquisition of Triptorelin 11.25 mg (AQ2023-671)

This tender, designated as SP 996-2026, is for the acquisition of Triptorelin 11.25 mg, with an associated reference AQ2023-671. This indicates a procurement of pharmaceutical goods, specifically a medication used in various medical treatments, likely related to hormonal therapies. The tender is for the year 2026. While the contracting authority and specific procurement method are not detailed in the title, it is understood to be a goods procurement. The acquisition of Triptorelin is critical for healthcare providers requiring this specific dosage and formulation for patient treatment. Potential suppliers of pharmaceutical products are invited to respond to this tender. Further information regarding the tender process, including submission requirements, deadlines, and detailed specifications, would be available in the full tender documents.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 4,449.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.